文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

ATG对比塞替派联合白消安和环磷酰胺在重型地中海贫血匹配相关骨髓移植中的比较

ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia.
PubMed 文献 · Blood Adv · 2017-05-11

该回顾性研究比较了81例低危重型地中海贫血患者接受匹配相关骨髓移植时,在白消安-环磷酰胺(BuCy)基础上加用塞替派(Tt)或抗胸腺细胞球蛋白(ATG)的结局。Tt-BuCy组30例,ATG-BuCy组51例,中位随访分别为37个月和17个月。两组总生存率分别为87%和94%,无地中海贫血生存率分别为80%和85%,log-rank检验无显著差异。作者认为在标准BuCy方案中以ATG替代Tt似乎安全有效,可能降低移植相关死亡率,并预期接受ATG-BuCy的患者生育率更高。

要点

  • 在81例低危重型地中海贫血患儿中,Tt-BuCy组总生存87%、无地中海贫血生存80%,ATG-BuCy组分别为94%和85%,log-rank检验无显著差异。
  • 中位随访时间Tt-BuCy组为37个月,ATG-BuCy组为17个月。
  • 作者认为在标准BuCy方案中以ATG替代Tt似乎安全有效,可能降低移植相关死亡率,并预期接受ATG-BuCy的患者生育率更高。

核心结论

  • 在标准BuCy方案中以ATG替代Tt似乎安全有效,可能降低移植相关死亡率。
  • 预期接受ATG-BuCy的患者生育率更高。

研究设计与样本

  • 回顾性比较研究,纳入2009年1月至2016年1月间在印度次大陆5个合作初创骨髓移植中心连续进行的81例首次匹配相关骨髓移植。
  • 2009年1月至2013年7月间30例患者接受Tt-BuCy预处理,2013年8月至2016年1月间51例患者接受ATG-BuCy预处理。
  • 所有患者年龄<15岁,无肝肿大(肝脏≤肋缘下2 cm)。

主要发现

  • Tt-BuCy组和ATG-BuCy组的总生存率分别为87%和94%,无地中海贫血生存率分别为80%和85%,中位随访分别为37个月和17个月。
  • 两组生存曲线经log-rank检验无显著差异。

临床怎么用

  • 作者认为在标准BuCy方案中以ATG替代Tt似乎安全有效,可能降低移植相关死亡率。
  • 作者预期接受ATG-BuCy的患者生育率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Matched-related bone marrow transplantation (BMT) may cure >80% of low-risk children with severe thalassemia (ST). Very long-term follow-up studies have shown how the standard busulfan-cyclophosphamide (BuCy) regimen may be associated with normalization of health-related quality of life, no second malignancies in the absence of chronic graft-versus-host disease, and fertility preservation in many patients. However, because BuCy may be associated with high rejection rates, some centers incorporate thiotepa (Tt) in busulfan- or treosulfan-based regimens, a combination that may increase the risk of permanent infertility. This study retrospectively compares matched-related BMT outcomes in 2 groups of low-risk ST patients conditioned with either Tt or anti-thymocyte globulin (ATG) in addition to BuCy. A total of 81 consecutive first BMTs were performed in 5 collaborating startup BMT centers in the Indian subcontinent between January 2009 and January 2016; 30 patients were transplanted after conditioning with Tt-BuCy between January 2009 and July 2013, whereas between August 2013 and January 2016, 51 patients received ATG-BuCy. All patients were <15 years and had no hepatomegaly (liver ≤2 cm from costal margin). Actuarial overall survival in the Tt-BuCy and ATG-BuCy groups was 87% and 94% and thalassemia-free survival was 80% and 85% at a median follow-up of 37 and 17 months, respectively, with no significant differences by log-rank statistics. Substituting Tt with ATG in the standard BuCy context seems safe and effective and may decrease transplant-related mortality. Higher fertility rates are expected for patients who received ATG-BuCy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Faulkner L, Uderzo C, Khalid S, et al. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017. PMID: 29296723. doi:10.1182/bloodadvances.2016004119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。